Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20312792 | 0.77 | MEN1 (0.33) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL25949857 | 0.77 | — | — | |
| SCHEMBL22861897 | 0.71 | — | — | |
| SCHEMBL14329650 | 0.68 | MEN1 (0.33) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL13306767 | 0.66 | ALDH1A1 (0.31) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL5530477 | 0.66 | CNR1 (0.33) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL14329578 | 0.66 | HEXA (0.31) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL14329572 | 0.64 | MEN1 (0.30) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL22966581 | 0.63 | GSR (0.37) | MEN1KMT2A | |
| SCHEMBL9643564 | 0.63 | MEN1 (0.39) | MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-10806785-B2 | Immunomodulator compounds and methods of use | INCYTE CORPORATION (US) | 2020-10-20 | — | — | US | disclosed |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MEN1 1546/4885CYP1A2 414/4885KMT2A 4066/4885 |
| US-10806785-B2 | Immunomodulator compounds and methods of use | CD274, PDCD1LG2, PDCD1 | MEN1 3586/4885CYP1A2 4623/4885KMT2A 4262/4885 |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | MEN1 3586/4885CYP1A2 4623/4885KMT2A 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.